Who was studied, and how
Five numbers in the abstract
Where each one falls
Where it lands on the map
people with type 2 diabetes, in this paper
Already taking metformin use, or nottheir own situation, not assigned
on metformin use
not on metformin use
Metformin use went with lower overall cancer−45%
Metformin use went with lower gastrointestinal cancer risk−21%
Metformin use went with lower urologic cancer risk−12%
correlation, not a testthe abstract, start to end
… observed in case-control studies (RR = 0.55, 95% confidence interval [CI] = 0.30 to 0.80) and prospective cohort studies (RR = 0.65, 95% CI = 0.37 to 0.93).
… with reduced gastrointestinal (RR = 0.79, 95% CI = 0.73 to 0.85), urologic (RR = 0.88, 95% CI = 0.78 to 0.99), and hematologic (RR = 0.87, 95% CI = 0.75 to 0.99) cancer …
← favours treatmentfavours comparator →
could be chanceOverall cancermetformin use vs no metformin use, in case-control studies
RR 0.550.30–0.80
Overall cancermetformin use vs no metformin use, in prospective cohort studies
RR 0.650.37–0.93
Gastrointestinal cancer riskmetformin use vs no metformin use
RR 0.790.73–0.85
Urologic cancer riskmetformin use vs no metformin use
RR 0.880.78–0.99
Hematologic cancer riskmetformin use vs no metformin use
RR 0.870.75–0.99
MetforminAdverse events & safety
1 / 4